Waldenström's macroglobulinemia diagnostic study of choice: Difference between revisions
| Line 6: | Line 6: | ||
The diagnosis of Waldenström macroglobulinemia is based on bone marrow biopsy and serum protein analysis. | The diagnosis of Waldenström macroglobulinemia is based on bone marrow biopsy and serum protein analysis. | ||
== Diagnostic study of choice == | == Diagnostic study of choice == | ||
=== Diagnostic study of choice === | |||
There is no single diagnostic study of choice for the diagnosis of Waldenström macroglobulinemia, but WM can be diagnosed based on a bone marrow biopsy and monoclonal protein studies.<ref name="pmid15735132">{{cite journal| author=Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP| title=Diagnosis and management of Waldenstrom's macroglobulinemia. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 7 | pages= 1564-77 | pmid=15735132 | doi=10.1200/JCO.2005.03.144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735132 }} </ref><ref name="pmid26980727">{{cite journal| author=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al.| title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms. | journal=Blood | year= 2016 | volume= 127 | issue= 20 | pages= 2375-90 | pmid=26980727 | doi=10.1182/blood-2016-01-643569 | pmc=4874220 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26980727 }} </ref> | |||
=== Diagnostic results === | |||
The following findings on performing bone marrow biopsy and serum protein analysis are suggestive of Waldenström macroglobulinemia:<ref name="pmid15735132" /> | |||
* A significant IgM monoclonal gammopathy on serum protein analysis | |||
* A bone marrow biopsy demonstrating more than 10% infiltration by small lymphocytes with an intertrabecular pattern and expressing a typical immunophenotype | |||
==References== | ==References== | ||
Revision as of 23:14, 30 October 2018
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia diagnostic study of choice |
|
FDA on Waldenström's macroglobulinemia diagnostic study of choice |
|
CDC on Waldenström's macroglobulinemia diagnostic study of choice |
|
Waldenström's macroglobulinemia diagnostic study of choice in the news |
|
Blogs on Waldenström's macroglobulinemia diagnostic study of choice |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roukoz A. Karam, M.D.[2]
Overview
The diagnosis of Waldenström macroglobulinemia is based on bone marrow biopsy and serum protein analysis.
Diagnostic study of choice
Diagnostic study of choice
There is no single diagnostic study of choice for the diagnosis of Waldenström macroglobulinemia, but WM can be diagnosed based on a bone marrow biopsy and monoclonal protein studies.[1][2]
Diagnostic results
The following findings on performing bone marrow biopsy and serum protein analysis are suggestive of Waldenström macroglobulinemia:[1]
- A significant IgM monoclonal gammopathy on serum protein analysis
- A bone marrow biopsy demonstrating more than 10% infiltration by small lymphocytes with an intertrabecular pattern and expressing a typical immunophenotype
References
- ↑ 1.0 1.1 Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.
- ↑ Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R; et al. (2016). "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.